CDKN2A and melanoma: After testing a number of different approaches we suggested a pipeline for the functional analysis that could be applied to characterize any new variant identified in the CDKN2A 5`UTR, starting from gene reporter assays based on bicistronic vectors in one melanoma cell line (like WM266-4), integrated with polysomal profiling and p16 INK4a protein expression studies.